Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. It develops orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. It also develops SFX-01, that has completed phase I for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Metrics to compare | TCF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTCFPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.6x | −3.1x | −0.5x | |
PEG Ratio | −0.04 | −0.04 | 0.00 | |
Price/Book | 0.9x | 2.7x | 2.6x | |
Price / LTM Sales | - | 16.0x | 3.0x | |
Upside (Analyst Target) | - | 154.2% | 52.6% | |
Fair Value Upside | Unlock | −12.8% | 8.8% | Unlock |